DDInter556 DDInter233
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may lead to a major life threatening interaction when taken with {v} Fentanyl
Fentanyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valdecoxib
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Codeine
Codeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydrocodeine (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib